Important NoticeThis app is for educational purposes only. You must be 18+ to use it. We do not sell any peptides on this site.

Research Use Only - Important Disclaimer

All products listed on this website are intended for laboratory research use only and are not for human consumption, medical, veterinary, or household use. These products should only be handled by qualified professionals. We do not provide any dosage information, and the products must not be used as food additives, drugs, cosmetics, or for any other inappropriate applications. By purchasing, you acknowledge and agree to these terms.

Vial

Survodutide

Dual GLP-1/Glucagon Receptor Agonist (Oxyntomodulin-Class)For research use only
View

Survodutide (BI 456906) is a long-acting peptide that co-activates GLP-1 and glucagon receptors, designed to deliver robust body-weight reduction by coupling GL…

Half-life

Approximately 1 week (supports once-weekly dosing)

Delivery

Once-weekly subcutaneous injection

Suggested dosage

Not specified

Usage

Studied for chronic weight management and metabolic disease, including obesity and metabolic dysfunction–associated steatohepatitis (MASH).

Mechanism of action

Agonism at GLP-1R enhances glucose-dependent insulin secretion, slows gastric emptying, reduces appetite, and suppresses inappropriate glucagon; concurrent GCGR activation increases energy expenditure and promotes fatty-acid oxidation. The combined signaling can yield greater weight loss than GLP-1–only agonism.

Benefits (4)

  • Clinically meaningful body-weight reduction (once-weekly dosing)
  • Improved glycemic and cardiometabolic markers in study populations
  • Reductions in liver fat and MASH-related biomarkers in trials
  • Potential improvements in waist circumference and lipid parameters

Side effects (5)

  • Class-typical GI effects (nausea, vomiting, diarrhea/constipation)
  • Decreased appetite
  • Injection-site reactions
  • Possible mild heart-rate increase (glucagon component, dose-dependent)
  • Rare: gallbladder disease or pancreatitis (incretin class consideration)
No purchase links available